Close
Open Nav
2019 Schedule of Events

Tuesday, March 5, 2019

7:00 AM - 6:00 PM

Partnering Desk Open

7:00 AM - 6:00 PM

Registration Open

7:00 AM - 9:00 AM Networking Breakfast
8:00 AM - 6:00 PM BIO One-on-One PartneringTM Meetings

9:00 AM - 9:15 AM

Welcome and Opening Remarks

9:15 AM - 10:00 AM

Company Presentations

9:15 AM - 10:00 AM

How is the Drug Pricing Reform Initiative Affecting Patient Access, Investment, and Innovation in Japan?

10:00 AM - 10:30 AM

Refreshment Break

10:15 AM - 10:55 AM Reshaping Tumor Microenvironments via Immunotherapies
10:15 AM - 12:00 PM Company Presentations

11:00 AM - 11:55 AM

Turning RNA Interference Research into Medicines

12:45 PM - 1:30 PM

Keynote Chat: Dr. Tatsuya Kondo, Chief Executive, PMDA

1:45 PM - 6:00 PM Company Presentations
2:00 PM - 2:55 PM

Bridging External Innovation and Internal R&D for New Patient Therapies

3:00 PM - 3:30 PM Refreshment Break

3:00 PM - 3:55 PM

Explaining CFIUS and New Investment Regulations in the United States

4:00 PM - 4:25 PM

Access as a Policy Choice: Measuring Openness to Innovation & Creativity

4:30 PM - 5:25 PM

Market Outlook - Finding Opportunties During Global Trade Downturns

6:00 PM - 7:30 PM Welcome Reception

 

Wednesday, March 6, 2019

7:30 AM - 5:00 PM Registration Open
7:30 AM - 9:00 AM Networking Breakfast
7:30 AM - 6:00 PM Partnering Desk Open
8:00 AM - 6:00 PM BIO One-on-One PartneringTM Meetings

8:30 AM - 12:00 PM

Company Presentations

9:00 AM  - 9:55 AM

Deploying Artificial Intelligence (AI) to Improve R&D Productivity

10:00 AM - 10:55 AM

Biotech Incubator Business Models: Lessons and Needed Improvements

10:00 AM - 10:30 AM

Refreshment Break

11:00 AM - 11:55 AM

Using M&A for Data Advantages Beyond Product Pipelines

12:00 PM  - 1:30 PM

Keynote Chat: BT Slingsby, MD, PhD, MPH, CEO & Executive Director, Global Health Innovative Technology (GHIT) Fund

1:45 PM  - 4:30 PM Company Presentations

2:30 PM  - 3:00 PM

Refreshment Break
2:00 PM - 2:55 PM Crafting a Global Clinical Trials Strategy: Partner Selection and Regulatory Risk